A probe finds several pharma majors in breach of the law; and in turn they blame the government.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Face NPPA fine for overcharging on anti-asthma drug
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Fearing outbreak of epidemics, the ministry is sending a high level team to review the public health measures in the area
FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
Data also show that several other leading domestic pharma companies have recalled their products from the US
The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.
In a development that could hasten the entry of the generic version of Gleevec into the US market, Indian drug major Sun Pharma has sued Novartis Pharmaceuticals Corp in the District Court of New Jersey, demanding rights to launch a generic version of the cancer drug before the Novartis patent expires.
Last month, the US Food and Drugs Administration had placed Wockhardt's facilities in Waluj near Aurangabad on import alert, barring supply of various products from these facilities to the US.
The complaint was lodged by Mumbai-based Express Industry Council of India, which represented major express courier and cargo companies such as DTDC, Aramex India, Blue Dart, DHL Express, GATI and First Flight.
FDA had also issued warning letters to Ranbaxy's Paonta Sahib and Dewas facilities as it found extensive problems and deviations from manufacturing norms.
There may be shortage of drugs till pharmaceutical companies supply new batches with revised MRPs.
Apollo Pharmacy, the country's largest branded drug retail network with over 1,500 outlets, has temporarily suspended sale of medicines manufactured by Ranbaxy Laboratories. It has also stopped further procurement from the company for now.
The 2008 deal agreement contains provisions of arbitration to be held in that country.
Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
The trouble-stricken company has sought appointment with at least two major hospitals -- Mumbai-based Jaslok and Gurgaon-based Medanta Medicity.
The company was indicted for violations at one of its US facilities in 2009, even after Daiichi Sankyo took over as majority shareholder in 2008.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances